THERAVANCE BIOPHARMA INC

Insider selling at Theravance Biopharma remains steady amid its $929 million Zymeworks acquisition—investors see liquidity moves, not a crisis.

Theravance insider sale: SVP Rhonda Farnum sells 13,314 shares at $16.39, yet her holdings remain 27%—a routine liquidation amid strong stock performance and pipeline growth.

Theravance Biopharma insider buys spark debate: CEO’s new 75,000‑share purchase amid a failed CYPRESS trial and pipeline prospects for TC‑305, TC‑410, and TC‑512 – what investors should watch.

Insider sale by Theravance CEO shows routine tax‑planning, not a confidence loss—company’s strong pipeline, valuation, and market buzz keep investors on alert.